AtriCure, Inc.
AtriCure (NASDAQ:ATRC) Board Member Regina E Groves sold 5,313 shares for $288,070 on September 14, according to an SEC filing. ATRC shares were down 0.97% at $55.79 on Tuesday. The company reported 12.83% revenue growth and a 77.23% gross margin as of June 30, 2026, but has a high P/E ratio of 265.67 and an EPS of 0.18.
GROVES REGINA E sold 5,313 shares of AtriCure, Inc. (ATRC) at $54.22 ($0.29M total) on 2026-09-11.
AtriCure CTO Salvatore Privitera sold 3,657 shares at $55.0 each, totaling $201,135. The sale was part of a 10b5-1 plan. AtriCure (ATRC) stock is near its 52-week high, up 51% in a year. The company reported strong Q2 2026 earnings, beating estimates, but stock fell on cautious outlook. Analysts raised price targets, citing positive catalysts.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ATRC (AtriCure, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ATRC coverage spans financial news, insider activity and market movers.
In the last 30 days, ATRC insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($1.4M). The most active reporter was Privitera Salvatore, Chief Technical Officer, with 2 filings. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
Small insider sell with modest price dip; unlikely to drive significant price movement.
Minor dilution of insider ownership; unlikely to move price materially.
Small insider sell likely has negligible impact on price.
Strong revenue growth and raised guidance suggest momentum in the cardiac‑device market.
Analyst upgrade may support short-term price appreciation.
AlphAI scores every news story that mentions ATRC with an AI model for sentiment and relevance, and aggregates insider trades from AtriCure, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AtriCure (NASDAQ:ATRC) Board Member Regina E Groves sold 5,313 shares for $288,070 on September 14, according to an SEC filing. ATRC shares were down 0.97% at $55.79 on Tuesday. The company reported 12.83% revenue growth and a 77.23% gross margin as of June 30, 2026, but has a high P/E ratio of 265.67 and an EPS of 0.18.
1 min readGROVES REGINA E sold 5,313 shares of AtriCure, Inc. (ATRC) at $54.22 ($0.29M total) on 2026-09-11.
1 min readAtriCure CTO Salvatore Privitera sold 3,657 shares at $55.0 each, totaling $201,135. The sale was part of a 10b5-1 plan. AtriCure (ATRC) stock is near its 52-week high, up 51% in a year. The company reported strong Q2 2026 earnings, beating estimates, but stock fell on cautious outlook. Analysts raised price targets, citing positive catalysts.
1 min readSeveral biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.
2 min readPiper Sandler maintained its Overweight rating for AtriCure (ATRC) and raised its price target from $50.00 to $60.00. The company's stock is currently trading at $48.16, which GuruFocus deems 21.6% overvalued. AtriCure has a GF Score of 79/100, indicating strong overall performance, but significant insider selling has occurred recently.
2 min readPiper Sandler raised its price target for AtriCure (NASDAQ:ATRC) to $60, citing a new quality measure for atrial fibrillation treatment as a catalyst. The firm expects market penetration to increase, driving growth. AtriCure's Q2 2026 earnings beat estimates, but shares fell on cautious outlook. BTIG also raised its target to $55.
2 min readDahlquist Karl S. (Chief Legal Officer) sold 9,370 shares of AtriCure, Inc. (ATRC) at $48.89 ($0.46M total) on 2026-08-24.
1 min readWall Street analysts updated price targets and ratings for several companies. Baird cut Chipotle's (CMG) target to $40 and downgraded it to Neutral. HC Wainwright raised LB Pharmaceuticals' (LBRX) target to $60. BTIG increased AtriCure's (ATRC) target to $55. Baird also raised Analog Devices' (ADI) target to $675 and upgraded Darden Restaurants' (DRI) target to $250. Other notable changes include updates for Black Rock Coffee Bar (BRCB), Marti Technologies (MRT), Alkami Technology (ALKT), Chenie
2 min readSeveral biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.
3 min readAtriCure (NASDAQ:ATRC) director Maggie Yuen sold 3,500 shares on Aug. 5, 2026 for about $134,470, at a weighted average $38.42, leaving 14,015 shares. The article also cites AtriCure’s 2Q revenue up 13% to $154 million, gross margin at 77%, and a raised full-year outlook.
4 min read
